ImageneBio, Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
IMA$3.81-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| License revenue | $— | $3,500 | $800 | $3,500 |
| Operating expenses: | ||||
| Research and development (1) | 15,558 | 3,885 | 25,251 | 28,350 |
| General and administrative | 11,036 | 1,651 | 15,496 | 6,008 |
| Total operating expenses | 26,594 | 5,536 | 40,747 | 34,358 |
| Loss from operations | (26,594) | (2,036) | (39,947) | (30,858) |
| Other income (expense): | ||||
| Interest income (expense), net | (96) | 46 | (409) | 344 |
| Other income (expense), net | 1,837 | (1,193) | 1,841 | (1,242) |
| Total other income (expense), net | 1,741 | (1,147) | 1,432 | (898) |
| Loss before income taxes | (24,853) | (3,183) | (38,515) | (31,756) |
| Income tax benefit | (74) | — | (74) | — |
| Net loss | $(24,779) | $(3,183) | $(38,441) | $(31,756) |
| Accretion of redeemable convertible preferred shares | (846) | (2,998) | (7,046) | (8,757) |
| Net loss attributable to common stockholders | $(25,625) | $(6,181) | $(45,487) | $(40,513) |
| Loss per share – basic and diluted: | ||||
| Common stock | $(2.91) | $(2.58) | $(9.98) | $(19.14) |
| Series A convertible preferred shares | $(2.91) | $(2.58) | $(9.98) | $(19.14) |
| Weighted average shares used to compute basic and diluted loss per share: | ||||
| Common stock | 8,526,781 | 1,400,557 | 3,808,867 | 1,121,742 |
| Series A convertible preferred shares | 270,345 | 994,869 | 750,707 | 994,869 |
| Comprehensive loss: | ||||
| Net loss | $(24,779) | $(3,183) | $(38,441) | $(31,756) |
| Other comprehensive loss: | ||||
| Unrealized gain on marketable securities | 94 | — | 94 | — |
| Foreign currency translation adjustment | (3) | 2 | (29) | (98) |
| Total comprehensive loss | $(24,688) | $(3,181) | $(38,376) | $(31,854) |
(1)
Includes related party amount of $0.4 million for the three and nine months ended September 30, 2025, respectively, andzero for the three and nine months ended September 30, 2024, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.